Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'

• Published in: AIDS (London) Vol. 21; no. 18; p. 2566
• Main Authors: Pedrol, Enric, Deig, Elisabet
• Format: Journal Article
• Language: English
• Published: England 30.11.2007
• Subjects: Adenine - adverse effects; Adenine - analogs & derivatives; Adult; Anti-HIV Agents - adverse effects; Antiretroviral Therapy, Highly Active - adverse effects; Female; Glomerular Filtration Rate - drug effects; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Kidney - drug effects; Male; Organophosphonates - adverse effects; Retrospective Studies; Tenofovir
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/QAD.0b013e3282f13a62

Crane et al. recently reported the evolution of kidney function in a group of patients who were receiving a tenofovir-based treatment, concluding that the concomitant use of amprenavir or didanosine was associated with an increased risk of kidney function decline. We would like to share our experience with the PROTECTION cohort. This cohort is an observational, retrospective cohort collecting data from 75 HIV units in Spain of patients who were taking a tenofovir plus protease inhibitor-containing regimen [2-5]. The study period ranged from July 2002 (the first date in which tenofovir became commercially available in Spain) until July 2006. A total of 1428 patients were included in the cohort. Among several other parameters, we have assessed the evolution of kidney function both in the global cohort and in different protease inhibitor-based subsets.